These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 20397815)

  • 1. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.
    Gross NJ; Giembycz MA; Rennard SI
    COPD; 2010 Apr; 7(2):141-53. PubMed ID: 20397815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
    Karish SB; Gagnon JM
    Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].
    Kreutzkamp B
    Med Monatsschr Pharm; 2010 Jul; 33(7):236-43. PubMed ID: 20687460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roflumilast for asthma and chronic obstructive pulmonary disease.
    Cowan C
    Issues Emerg Health Technol; 2005 Oct; (74):1-4. PubMed ID: 16317827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
    Pinner NA; Hamilton LA; Hughes A
    Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roflumilast: a novel treatment for chronic obstructive pulmonary disease.
    Reid DJ; Pham NT
    Ann Pharmacother; 2012 Apr; 46(4):521-9. PubMed ID: 22433610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
    Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
    Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roflumilast: doubtful efficacy but clear harms in COPD.
    Prescrire Int; 2013 Jan; 22(134):5-9. PubMed ID: 23367674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roflumilast for the treatment of chronic obstructive pulmonary disease.
    Antoniu SA
    Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roflumilast: clinical benefit in patients suffering from COPD.
    Ulrik CS; Calverley PM
    Clin Respir J; 2010 Oct; 4(4):197-201. PubMed ID: 20887341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roflumilast for the treatment of chronic obstructive pulmonary disease.
    Rabe KF
    Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
    Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE
    Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
    Fabbri LM; Calverley PM; Izquierdo-Alonso JL; Bundschuh DS; Brose M; Martinez FJ; Rabe KF;
    Lancet; 2009 Aug; 374(9691):695-703. PubMed ID: 19716961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
    Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
    Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD.
    Tashkin DP
    Expert Opin Pharmacother; 2014 Jan; 15(1):85-96. PubMed ID: 24032576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions.
    van Schalkwyk E; Strydom K; Williams Z; Venter L; Leichtl S; Schmid-Wirlitsch C; Bredenbröker D; Bardin PG
    J Allergy Clin Immunol; 2005 Aug; 116(2):292-8. PubMed ID: 16083782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical profile of roflumilast].
    Izquierdo Alonso JL
    Arch Bronconeumol; 2010 Dec; 46 Suppl 10():25-32. PubMed ID: 21316553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
    Giembycz MA; Field SK
    Drug Des Devel Ther; 2010 Jul; 4():147-58. PubMed ID: 20689641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.